On Monday, North Atlantic Drilling Ltd. (NYSE:NADL)’s shares declined -3.27% to $1.48.
North Atlantic Drilling Ltd. (NADL) is planned to release its first quarter and 2015 results on Thursday May 28, 2015.
Administration will address highlights from North Atlantic Drilling’s first quarter 2015 results in a conference call to be held at 11:00 a.m. EDT / 5:00 p.m. CEST on Thursday May 28, 2015.
North Atlantic Drilling Limited operates as an offshore drilling services contractor in the North Atlantic region. The company provides harsh environment offshore drilling services to the oil and gas industry primarily in Norway and the United Kingdom.
Transocean LTD (NYSE:RIG)’s shares dropped -3.08% to $20.15.
Transocean LTD (RIG) declared the plan for the payment of the first installment of its U.S. dollar-denominated dividend. The installment is $0.15 per share, totaling about $55 million based upon the number of presently outstanding shares. The installment represents the first of four quarterly installments totaling $0.60 per share, or about $218 million in the aggregate paid from additional paid-in capital (“APIC”), approved by shareholders at the company`s 2015 Annual General Meeting.
Dividend Plan - First Installment
- May 27, 2015 - Ex-Dividend Date
- May 29, 2015 - Record Date
- June 17, 2015 - Installment Payment Date
Currency Election Period
Shareholders who wish to receive the payment in Swiss francs (“CHF”) must make their election between 5 p.m. EDT (11 p.m. CEST) on June 1, 2015 and 8 p.m. EDT on June 5, 2015 (2 a.m. CEST June 6, 2015). On or about June 15, 2015, the dividend payment will be converted into CHF by Computershare and the equivalent CHF per share will be posted to the company`s website at www.deepwater.com.
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services.
At the end of Monday’s trade, Sanchez Energy Corp (NYSE:SN)‘s shares dipped -3.00% to $11.32.
Sanchez Energy Corp (SN) declared that Gleeson Van Riet has been named Senior Vice President and Chief Financial Officer of the Company, effective right away.
Preceding to this appointment, Mr. Van Riet served as Senior Vice President, Capital Markets and Investor Relations, since April 2013 and as Interim Co-Chief Financial Officer since March 2015.
Tony Sanchez, III, President and Chief Executive Officer of Sanchez Energy stated that Gleeson has achieved strong results in his previous roles with their company, and they are very happy with the job he has done leading their finance team as Interim Co-Chief Financial Officer since he took on that role in March. “During the executive search process Gleeson stood out given his knowledge of the company and his success in the roles he has undertaken thus far.
Sanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition, exploration, and development of unconventional oil and natural gas resources in the onshore U.S. Gulf Coast.
Galena Biopharma Inc (NASDAQ:GALE), ended its Monday’s trading session with -2.96% loss, and closed at $1.31.
Galena Biopharma Inc (GALE) stated its financial results for the quarter ended March 31, 2015 and offered a business update.
FINANCIAL HIGHLIGHTS AND GUIDANCE
Company recognize revenue from the sale of Abstral to wholesale pharmaceutical distributors, net of product-related discounts, allowances, product returns, rebates, chargeback’s, and patient assistance benefits, as applicable. Net revenue was $2.8 million in the first quarter of 2015, a 28% enhance contrast to $2.2 million for the same period a year ago.
Operating loss for the first quarter of 2015 was $11.1 million, counting $0.6 million in stock based compensation, contrast to an operating loss of $11.8 million, counting $1.7 million in stock-based compensation for the same period in 2014. The decrease in net operating loss year-over-year is primarily the result of the completion of enrollment in our Phase 3 PRESENT trial for NeuVax, in addition to the decrease in stock based compensation.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
